Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,462.03
(
0.34%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: biopharm post# 179501

Tuesday, 06/10/2014 6:40:56 PM

Tuesday, June 10, 2014 6:40:56 PM

Post# of 347009
Why is Hatfield now on BOD of Ambit ? We know Peregrine&Ambit are working together...and BMS/Ambit already have a working relationship/collaboration.

Jeffrey Hatfield video: 2013



http://www.ambitbio.com/Board_of_Directors

.... maybe BMS will be buying out a couple more companies, because CEO of Vitae is welcomed to the BOD at Ambit for no reason at all

This all part of the Peregrine play by BMS? possibly... listen to the video and Alzheimers, diabetes..etc and he also mentions "tax reform" ... remember the article he just wrote (yesterday!) in the post this is replied from as well...

just trying to put some more puzzle pieces together...

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote